Assessment of fecal calprotectin, a surrogate marker of mucosal inflammation, is a promising means to monitor therapeutic response in pediatric inflammatory bowel disease, especially if the result is readily available. We tested the performance of a novel calprotectin rapid test, Quantum Blue, versus the conventional enzyme-linked immunosorbent assay in 134 stool samples from 56 pediatric patients with Crohn disease. The intraclass correlation coefficient analysis reflected good agreement (intraclass correlation coefficient 0.97 [95% confidence interval 0.95-0.98]) but agreement was better in lower values, where dilutions were not required. Using a cutoff of 100μg/g for normal values, the percentage agreement between the 2 tests was 87%. The optimal cutoff values to guide clinical decisions in the therapy of inflammatory bowel disease have yet to be determined. Copyright

Fecal biomarkers, Inflammatory bowel disease, Pediatric,
Journal of Pediatric Gastroenterology and Nutrition
Department of Pediatrics

Kolho, K.-L, Turner, D, Veereman-Wauters, G, Sładek, M, de Ridder, L, Shaoul, R, … Veres, G. (2012). Rapid test for fecal calprotectin levels in children with Crohn disease. Journal of Pediatric Gastroenterology and Nutrition, 55(4), 436–439. doi:10.1097/MPG.0b013e318253cff1